Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions

被引：0
|
作者：
Ma, H. [1 ]
Huang, H. [2 ]
Feng, Y. [2 ]
Chen, S. [2 ]
Li, G. [2 ]
机构：
[1] Soochow Univ, Dushu Lake Hosp, Suzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Adjuvant; Aumolertinib; Ground-glass opacity;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP07.05-05
引用
收藏
页码：S559 / S560
页数：2
相关论文
共 50 条
  • [41] A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer
    Lara-Mejia, Luis
    Sanchez-Reyes, Roberto
    Aviles-Salas, Alejandro
    Arrieta-Rodriguez, Oscar
    ONCOLOGY-NEW YORK, 2020, 34 (01): : 21 - 27
  • [42] Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
    Yoshiya Matsumoto
    Tomoya Kawaguchi
    Masaru Watanabe
    Shun-ichi Isa
    Masahiko Ando
    Akihiro Tamiya
    Akihito Kubo
    Chiyoe Kitagawa
    Naoki Yoshimoto
    Yasuhiro Koh
    BMC Cancer, 22
  • [43] Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer
    Matsumoto, Yoshiya
    Kawaguchi, Tomoya
    Watanabe, Masaru
    Isa, Shun-ichi
    Ando, Masahiko
    Tamiya, Akihiro
    Kubo, Akihito
    Kitagawa, Chiyoe
    Yoshimoto, Naoki
    Koh, Yasuhiro
    BMC CANCER, 2022, 22 (01)
  • [44] Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
    Feng, Siyang
    Wang, Yuanyuan
    Cai, Kaican
    Wu, Hua
    Xiong, Gang
    Wang, Haofei
    Zhang, Ziliang
    PLOS ONE, 2015, 10 (10):
  • [45] Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
    Liang, Y.
    Krupsky, K.
    Lankin, J.
    Cohn, J.
    Kashine, N.
    Honomichl, R.
    Rattigan-Brown, Y.
    Shehu, A.
    Salomonsen, R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S553 - S553
  • [46] Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
    Cai, Kaican
    Feng, Siyang
    Wang, Yuanyuan
    Wu, Hua
    Xiong, Gang
    Wang, Haofei
    Zhang, Ziliang
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S383 - S383
  • [47] A population-adjusted indirect treatment comparison of efficacy and safety of aumolertinib vs osimertinib in EGFR-mutated non-small cell lung cancer
    King, Sarah
    Stergiopoulos, Stella
    Curtis, Melissa
    Dillon, Andrew
    Akehurst, Ron
    Lee, Dawn
    Guelfucci, Florent
    Ngami, Armel
    Bianic, Florence
    Li, You
    Ma, Xiwen
    Ali, Siraj
    Miller, Vincent
    Popat, Sanjay
    LUNG CANCER, 2023, 178 : S36 - S37
  • [48] Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis
    Tian, Wentao
    Tan, Nuopei
    Ke, Jiawen
    Zou, Ji'an
    Liu, Xiaohan
    Pan, Yue
    Zeng, Yue
    Peng, Yurong
    Wu, Fang
    FUTURE ONCOLOGY, 2022, 18 (21) : 2695 - 2708
  • [49] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Huo, Gengwei
    Song, Ying
    Liu, Wenjie
    Cao, Xuchen
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [50] MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib
    Yan, Dan
    Huelse, Justus
    Parker, Rebecca
    Tan, Zikang
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    CANCER RESEARCH, 2020, 80 (16)
12345